Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib

Pediatr Blood Cancer. 2012 Nov;59(5):928-9. doi: 10.1002/pbc.24148. Epub 2012 Apr 5.

Abstract

Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Child, Preschool
  • Eosinophilia* / complications
  • Eosinophilia* / drug therapy
  • Eosinophilia* / genetics
  • Eosinophilia* / pathology
  • Humans
  • Imatinib Mesylate
  • Infant, Newborn
  • Infant, Newborn, Diseases* / drug therapy
  • Infant, Newborn, Diseases* / genetics
  • Infant, Newborn, Diseases* / pathology
  • Male
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / congenital
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / pathology
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Receptor, Platelet-Derived Growth Factor beta / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor beta